Similar articles

• The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.

  Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT. Andriole GL, et al. J Clin Oncol. 1987 May;5(5):799-803. doi: 10.1200/JCO.1987.5.5.799. J Clin Oncol. 1987. PMID: 3106585
• Prophylaxis of haemorrhagic cystitis due to cyclophosphamide-conditioning for bone marrow transplantation.

  Link H, Neef V, Niethammer D, Wilms K. Link H, et al. Blut. 1981 Nov;43(5):329-30. doi: 10.1007/BF00320957. Blut. 1981. PMID: 6799018 No abstract available.
• Mesna versus forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplant patients (preliminary data).

  Hows J, Mehta A, Gordon-Smith EC. Hows J, et al. Cancer Treat Rev. 1983 Sep;10 Suppl A:53-6. doi: 10.1016/s0305-7372(83)80007-3. Cancer Treat Rev. 1983. PMID: 6414696 No abstract available.
• Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy.

  Haselberger MB, Schwinghammer TL. Haselberger MB, et al. Ann Pharmacother. 1995 Sep;29(9):918-21. doi: 10.1177/106002809502900914. Ann Pharmacother. 1995. PMID: 8547741 Review.
• Mesna--a short review.

  Shaw IC, Graham MI. Shaw IC, et al. Cancer Treat Rev. 1987 Jun;14(2):67-86. doi: 10.1016/0305-7372(87)90041-7. Cancer Treat Rev. 1987. PMID: 3119211 Review. No abstract available.